Diurnal blood glucose profiles in type 2 diabetic patients: Lost past or back to the future?;Les cycles glycemiques dans le diabete de type 2: Passe perdu ou retour vers le futur?

Diabetes and Metabolism

Volumn 25, Issue 6, 1999, Pages 526-531

  Monnier, L ^a   Avignon, A ^a   Virally, M L ^b   Guillausseau, P J ^b   Sauvanet, J P ^c  

^a LAPEYRONIE HOSPITAL   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; ANTIDIABETIC AGENT;

BLOOD GLUCOSE MONITORING; CIRCADIAN RHYTHM; GLUCOSE BLOOD LEVEL; HYPERINSULINEMIA; HYPOINSULINEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR; BLOOD; DIABETIC DIET; HUMAN; HYPERGLYCEMIA; METABOLISM; PATHOPHYSIOLOGY; POSTPRANDIAL STATE;

BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; POSTPRANDIAL PERIOD;

EID: 0033457860     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. UK Prospective Diabetes Study (UKPDS) group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837-853.
2. Laakso M, Lehto S. Epidemiology of macrovascular and microvascular disease in diabetes. Diabetes Rev, 1997, 5, 294-315.
3. Klein R. Hyperglycemia and microvascular disease in diabetes. Diabetes Care, 1995, 18, 258-268.
4. Anderson DKG, Svärdsudd K. Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care, 1995, 18, 1534-1543.
5. Buse JB. Overview of current therapeutic options in type 2 diabetes. Diabetes Care, 1999, 22 (suppl.3), C65-C70.
6. Monnier L, Colette C, Avignon A, Percheron C, Lapinski H, Boniface H. Le changement dans la prise en charge diététique du diabétique. Diabetes Metab, 1998, 24 (suppl.3), 24-34.
7. Balkau B, Shipley M, Jarrett JH, Pyörälä K, Pyörälä M, Forhan A, Eschwege E. High blood glucose concentration is a risk factor for mortality in middle-aged non diabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study and the Helsinki Policemen Study. Diabetes Care, 1998, 21, 360-367.
8. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Linder J. The DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM. The Diabetes Intervention Study. 11-year-follow-up. Diabetologia, 1996, 59, 1577-1583.
9. Mooradian AD, Thurman JE. Drug therapy of post prandial hyperglycemia. Drugs, 1999, 57, 19-29.
10. American Diabetes Association. Standards of Medical care for patients with diabetes mellitus. Diabetes Care, 1999, 22 (suppl 1), S32-S41.
11. Recommandations de l'ANAES. Suivi du patient diabétique de type 2 à l'exclusion du suivi des complications. Diabetes Metab, 1999, 25 (suppl 2), 1-64.
12. Avignon A, Radauceanu A, Monnier L. Non fasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care, 1997, 20, 1822-1826.
13. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E. Abnormal patterns of insulin secretion in non insulin dependent diabetes mellitus. N Engl J Med, 1988, 318, 1231-1239.
14. Trovati M, Burzacca S, Mularoni E, Massucco P, Cavalot F, Matteillo L, Anfossi G. Occurence of low blood glucose concentrations during the afternoon in type 2 (non insulin dependent) diabetic patients on oral hypoglycemic agents : importance of blood glucose monitoring. Diabetologia, 1991, 34, 662-667.
15. Guillausseau PJ. Monitoring of metabolic control in patients with non insulin-dependent diabetes mellitus on oral hypoglycaemic agents, value of evening blood glucose determination. Diabetic Med, 1997, 14, 798-802.
16. Watkins PJ. Guidelines for good practice in the diagnosis and treatment of non-insulin dependent diabetes mellitus. Report of a joint working party of the British Diabetic Asociation, the research unit of the Royal College of Physicians and the Royal College of General Practitioners. J Royal College of Physicians of London, 1993, 27, 259-266.
17. Alberti KGMM, Gries FA., Jervell J. Krans HMJ for the European NIDDM Policy Group. A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): an update. Diabetic Med, 1994, 11, 899-909.
18. Consensus statement. The Pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care, 1995, 18, 1510-1518.
19. Hay ward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes. JAMA, 1997, 178, 1663-1669.
20. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin diabetes mellitus. Drugs, 1995, 49, 721-749.
21. Yki-Järvinen H. Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia, 1995, 38, 1378-1388.
22. Golay A, Felber JP. Evolution from obesity to diabetes. Diab Metab, 1994, 20, 3-14.
23. Boden G, Chen X, Urbain JL. Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes, 1996, 45, 1044-1050.
24. Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in non-insulin dependent diabetes mellitus. N Engl J Med, 1992, 327, 707-713.
25. Lebovitz HE. a-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev, 1998, 6, 132-145.